Xcell Biologix, of Kennesaw, Georgia, said it entered an exclusive worldwide license agreement with the Wake Forest Institute for Regenerative Medicine, part of Wake Forest School of Medicine, for development and commercialization of its amnion-derived product candidates that accelerate wound closure and reepithelialization for the protection, healing and repair of chronic wounds and severe burns. Terms were not disclosed.